Dr. Malgorzata Mcmasters
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 31
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 161
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
MA license 240551
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Beth Israel Deaconess Medical Center Boston, MA
- Beth Israel Deaconess Hospital - Needham Needham, MA
Medical groups
- Harvard Medical Faculty Phys at Beth Israel Deaconess Med Ctr Inc (1,740 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 161
- Services billed
- 693
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 369 | 225 |
| Established patient office or other outpatient visit, 40-54 minutes | 267 | 112 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 121 | 37 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 19 | 12 |
| New patient office or other outpatient visit, 60-74 minutes | 19 | 19 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Jakafi (ruxolitinib phosphate) | 27 |
| Acyclovir Other prescribers in Boston, MA | 17 |
| Eliquis (apixaban) Other prescribers in Boston, MA | 13 |
| Prednisone Other prescribers in Boston, MA | 12 |
| Venclexta (venetoclax) | 12 |
| Rezurock (belumosudil mesylate) | 11 |
| Bosulif (bosutinib) | 11 |
| Sulfamethoxazole-Trimethoprim (sulfamethoxazole/trimethoprim) Other prescribers in Boston, MA | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 7 industry-funded studies in 2025, from 2 companies. The companies reported $327,716 in research payments for these studies, mostly to the institutions running them.
- A15-873;Venclexta;Bottle: ABT-199 100mg Yellow Film Coated Tablet 120 Tablets
AbbVie Inc. - A15-873;Venclexta;Blister Card: ABT-199 100mg Film-coated Tablet 2x8, 16 Tablets
AbbVie Inc. - A15-873;Venclexta;Blister Card: ABT-199 100mg Tablet, 1x8 Tablets
AbbVie Inc. - A Phase Ib Study of the Combination of Venetoclax with Chemotherapy as Frontline Therapy in Older Patients with Acute Lymphoblastic Leukemia (ALL)
AbbVie Inc. - A15-873;Venclexta;Blister Card: ABT-199 50mg Film-coated Tablet 1x8, 8 Tablets
AbbVie Inc. - A15-873;Venclexta;Blister Card: ABT-199 10mg Tablet 2x8, 16 Tablets
AbbVie Inc. - STML-401-0423 - a phase ii multicenter open -label trial of tagraxofusp (tag) in combination with venetoclax and azacitidine (ven/aza) in adults with previously untreated CD123+ acute myeloid leukemia (aml) who are i…
Stemline Therapeutics Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.